Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient

被引:9
作者
Lecefel, C. [1 ]
Eloy, P. [1 ]
Chauvin, B. [1 ]
Wyplosz, B. [2 ]
Amilien, V. [3 ]
Massias, L. [4 ]
Taburet, A. -M. [1 ]
Francois, H. [5 ]
Furlan, V. [1 ]
机构
[1] Hop Bicetre, AP HP, Le Kremlin Bicetre, France
[2] Hop Bicetre, AP HP, Infect Dis Clin Unit, Le Kremlin Bicetre, France
[3] Hop Bicetre, AP HP, Intens Care Unit, Le Kremlin Bicetre, France
[4] Bichat Claude Bernard Hosp, AP HP, Paris, France
[5] Hop Bicetre, AP HP, Dept Nephrol, Le Kremlin Bicetre, France
关键词
everolimus; interaction; pneumonitis; transplantation; voriconazole; CYTOCHROME-P450; 3A4; MTOR INHIBITORS; TACROLIMUS; MANAGEMENT; OUTCOMES;
D O I
10.1111/jcpt.12234
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objectiveAzole antifungals, prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients, can interact with drug substrates of CYP3A4. We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient. Case descriptionDespite reduction of the dose of everolimus by a third, the blood trough concentration of everolimus increased considerably in a kidney transplant recipient upon oral administration of voriconazole. Everolimus was then discontinued. Pneumonia secondary to pulmonary aspergillosis worsened, possibly due to the excessive immunosuppression. What is new and conclusionOrally administered voriconazole inhibits intestinal and hepatic cytochrome P450-3A4 activity and thereby reduces everolimus metabolism. An 80% decrease in dose or discontinuation of everolimus is required when concomitant voriconazole is introduced. Daily blood monitoring of everolimus is warranted until a steady state of concentrations is reached.
引用
收藏
页码:119 / 120
页数:2
相关论文
共 12 条
[1]   Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient [J].
Billaud, E. M. ;
Antoine, C. ;
Berge, M. ;
Abboud, I. ;
Lefeuvre, S. ;
Benammar, M. ;
Glotz, D. .
CLINICAL DRUG INVESTIGATION, 2009, 29 (07) :481-486
[2]   Risk Factors, Clinical Characteristics, and Outcomes of Invasive Fungal Infections in Solid Organ Transplant Recipients [J].
Bodro, M. ;
Sabe, N. ;
Gomila, A. ;
Ayats, J. ;
Baliellas, C. ;
Roca, J. ;
Melilli, E. ;
Carratala, J. .
TRANSPLANTATION PROCEEDINGS, 2012, 44 (09) :2682-2685
[3]   Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection [J].
Chhun, Stephanie ;
Rey, Elisabeth ;
Tran, Agnes ;
Lortholary, Olivier ;
Pons, Gerard ;
Jullien, Vincent .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2) :223-228
[4]   Clinical pharmacokinetics of everolimus [J].
Kirchner, GI ;
Meier-Wiedenbach, I ;
Manns, MP .
CLINICAL PHARMACOKINETICS, 2004, 43 (02) :83-95
[5]   Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole Blood [J].
Koster, Reinco A. ;
Dijkers, Eli C. F. ;
Uges, Donald R. A. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (01) :116-125
[6]   The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy [J].
Monaco, Anthony P. .
TRANSPLANTATION, 2009, 87 (02) :157-163
[7]   The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival [J].
Moroni, Gabriella ;
Longhi, Selena ;
Quaglini, Silvana ;
Gallelli, Beniamina ;
Banfi, Giovanni ;
Montagnino, Giuseppe ;
Messa, Piergiorgio .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (05) :1305-1314
[8]   Pharmacokinetic Interaction Between Everolimus and Antifungal Triazoles in a Liver Transplant Patient [J].
Pea, Federico ;
Baccarani, Umberto ;
Tavio, Marcello ;
Cojutti, Piergiorgio ;
Adani, Gian Luigi ;
Londero, Angela ;
Baraldo, Massimo ;
Franceschi, Loretta ;
Furlanut, Mario ;
Viale, Pierluigi .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (11) :1711-1716
[9]   Long-term outcome of everolimus treatment in transplant patients [J].
Salvadori, Maurizio ;
Bertoni, Elisabetta .
TRANSPLANT RESEARCH AND RISK MANAGEMENT, 2011, 3 :77-90
[10]   Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure-response relationships, and clinical outcomes [J].
Shihab, Fuad ;
Christians, Uwe ;
Smith, Lonnie ;
Wellen, Jason R. ;
Kaplan, Bruce .
TRANSPLANT IMMUNOLOGY, 2014, 31 (01) :22-32